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To make the appropriate developmental decisions or
maintain homeostasis, cells and organisms must coordi-
nate the expression of their genome and metabolic state.
However, the molecular mechanisms that relay environ-
mental cues such as nutrient availability to the appropri-
ate gene expression response remain poorly understood.
There is a growing awareness that central components
of intermediary metabolism are cofactors or cosubstrates
of chromatin-modifying enzymes. As such, their concen-
trations constitute a potential regulatory interface be-
tween the metabolic and chromatin states. In addition,
there is increasing evidence for a direct involvement of
classic metabolic enzymes in gene expression control.
These dual-function proteinsmay provide a direct link be-
tween metabolic programing and the control of gene ex-
pression. Here, we discuss our current understanding of
the molecular mechanisms connecting metabolism to
gene expression and their implications for development
and disease.
Metabolism and gene regulation are two fundamental bi-
ological processes that are essential to all living organ-
isms. Homeostasis, cell growth, and differentiation all
require the coordination of metabolic state and gene ex-
pression programs. Nevertheless, how expression of the
genome adapts to metabolic state or environmental
changes is not well understood. One level of regulation in-
volves signal transduction pathways that control key tran-
scription factors that act as master regulators of gene
expression programs. In addition, post-translational mod-
ifications (PTMs) of chromatin play a major role in the ac-
tivation or repression of gene transcription. These include
acetylation, methylation, and phosphorylation of the his-
tones and DNA methylation. Some of these chromatin
modifications are involved in the maintenance of stable
patterns of gene expression, usually referred to as epige-
netic regulation. Pertinently, the activity of enzymes
that modulate chromatin is critically dependent on cen-
tral metabolites as cofactors or cosubstrates. Thus, the
availability of metabolites that are required for the activi-
ty of histone-modifying enzymes may connect metabo-
lism to chromatin structure and gene expression.
Finally, selective metabolic enzymes act in the nucleus
to adjust gene transcription in response to changes inmet-
abolic state. Here, we review the interface between me-
tabolism and gene transcription. We focus on the
molecular mechanisms involved and discuss unresolved
issues and implications for development and disease.
The basics of metabolism and gene expression control
Metabolism is the total of all chemical reactions in cells
and organisms that maintain life. Metabolism can be di-
vided into two classes: catabolic processes (the breakdown
of molecules that usually results in the release of energy)
and anabolic processes (the synthesis of components such
as proteins, lipids, and nucleic acids, which costs energy).
Cellular (or intermediary) metabolism is organized in sep-
arate chemical pathways formed by a chain of linked enzy-
matic reactions in which the product of one step is the
substrate for the next. A small set of cofactors, nonprotein
compounds that are required for an enzymatic activity, is
used in a multitude of reactions to mediate the transfer of
chemical groups (see Tables 1, 2 for abbreviations of key
metabolites and metabolic enzymes). A classic example
is nicotinamide (NAM) adenine dinucleotide (NAD),
which exists in an oxidized (NAD+) or reduced (NADH)
form. NAD+ is used as an electron acceptor by dehydroge-
nases in a wide variety of pathways to remove electrons
from their substrate, producing NADH. Conversely,
NADHserves as an electron donor for reductases (yielding
NAD+). Thus, cofactors like NAD+/NADH are used
broadly and recycled continuously inmetabolic reactions.
In eukaryotic cells, the functional specialization of meta-
bolic pathways is enabled by compartmentalization. For
example, oxidative phosphorylation and the tricarboxylic
acid (TCA) cycle take place on the inner membrane of mi-
tochondria, but glycolysis occurs in the cytosol. The bulk
of intermediary metabolism happens in the cytoplasm,
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whereas the nucleus is largely dedicated to the replica-
tion, maintenance, and expression of the eukaryotic ge-
nome (Fig. 1).
Control of gene expression underlies cell differentiation
and development and allows a cell to respond to signals
and environmental changes. Gene transcription by
DNA-dependent RNA polymerases is the primary level
at which genes are regulated. Eukaryotic nuclear genes
are transcribed by three different RNA polymerases (poly-
merase I [Pol I], Pol II, and Pol III). RNA Pol I transcribes
most ribosomal RNA genes, whereas RNA Pol III tran-
scribesmainly tRNAs, 5SRNA, and someadditional small
Table 1. Metabolic enzymes and their function
Abbreviaon Enzyme Funcon 
ACADS 
(SCAD) 
Acyl-CoA dehydrogenase, C-2 to C-3 
short chain  
(short chain acyl-CoA dehydrogenase) 
Catalyzes the ﬁrst step in the β-oxidaon of short chain acyl-
CoA. Mitochondrial. 
ACLY 
(ACL) 
ATP-citrate lyase Cleaves citrate into acetyl-CoA and oxaloacetate.  
Cytosolic/nuclear. 
ACMSD 2-amino-3-carboxymuconate-6-
semialdehyde decarboxylase 
Catalyzes conversion of 2-amino-3-carboxymuconate-6-
semialdehyde into 2-aminomuconate-6-semialdehyde. 
Negavely regulates NAD+ synthesis from tryptophan 
ACSS1 
(AceCS2) 
Acyl-CoA synthetase short chain family 
member 1 
(Acetyl-CoA synthetase 2) 
Synthesizes acetyl-CoA from acetate.  Mitochondrial. 
ACSS2 
(AceCS1) 
Acyl-CoA synthetase short chain family 
member 2  
(Acetyl-CoA synthetase 1) 
Synthesizes acetyl-CoA from acetate. Cytosolic/nuclear. 
FBP1 Fructose-1,6-bisphosphatase Gluconeogenic enzyme. Catalyzes conversion of fructose 1,6-
bisphosphate into fructose 6-phosphate. Inhibitor of HIF 
transcriponal acvity. Cytosolic/nuclear. 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
Glycolyc enzyme. Catalyzes conversion of glyceraldehyde 3-
phosphate into 1,3-bisphosphoglycerate. Cytosolic/nuclear 
GDH Glutamate dehydrogenase Converts glutamate into α-ketoglutarate and NH4
+. 
Mitochondrial. 
GMPS GMP synthase Converts xanthosine 5’-monophosphate (XMP) into guanosine 
5’-monophosphate (GMP). Allosteric acvator of ubiquin 
speciﬁc protease 7 (USP7). Cytosolic/nuclear. 
IDH Isocitrate dehydrogenase Catalyzes the oxidaon of isocitrate into α-ketoglutarate . 
IDH2 and IDH3 are mitochondrial, IDH1 is cytosolic. 
IMPDH Inosine 5’-monophosphate 
dehydrogenase 
Catalyzes the oxidaon of inosine 5’-monophosphate (IMP) 
into xanthosine 5’-monophosphate (XMP). Binds sequence-
speciﬁc RNA and single stranded DNA. Two mammalian 
isozymes. Cytosolic/nuclear. 
MAT Methionine adenosyltransferase 
(SAM synthetase) 
Synthesizes SAM from ATP and methionine. Three mammalian 
isozymes. Cytosolic/nuclear. 
NAMPT Niconamide phosphoribosyltransferase Converts niconamide (NAM) into niconamide 
mononucleode (NMN). First and rate-liming step in the 
NAD+ salvage pathway. 
NMNAT Niconamide mononucleode 
adenylyltransferase 
Synthesizes NAD+ from niconamide mononucleode (NMN). 
Second step in the NAD+ salvage pathway. NMNAT1 is nuclear. 
NMNAT2 is cytosolic. NMNAT3 is mitochondrial. 
PDC Pyruvate dehydrogenase complex Catalyzes conversion of pyruvate into acetyl-CoA. 
Mitochondrial and nuclear. 
PDK Pyruvate dehydrogenase kinase Phosphorylates PDC, resulng in deacvaon of PDC. 
Mitochondrial. 
PK and PKM Pyruvate kinase Glycolyc enzyme. Catalyzes the conversion of 
phosphoenolpyruvate (PEP) and ADP into pyruvate and ATP. 
PKM2 isoform phosphorylates histone H3T11. 
PSAT1 Phosphoserine aminotransferase 1 Part of the serine biosynthec pathway. Catalyzes the 
conversion of 3-phosphopyruvate and glutamate into 3-
phosphoserine and α-ketoglutarate. 
SAHH S-adenosylhomocysteine hydrolase Catalyzes the conversion of SAH into homocysteine. Part of 
the methionine cycle. 
SHMT Serine hydroxymethyltransferase Catalyzes the conversion of serine and tetrahydrofolate (THF) 
in glycine and N5N10-methylene-tetrahydrofolate (CH2-THF). 
SHMT1 is cytosolic, SHMT2 is mitochondrial. 
List of metabolic enzymes discussed in the text. Abbreviations, functions, and subcellular localization are indicated.
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RNAs. Thus, Pol I and Pol III transcription is responsible
for major components of the protein synthesis machinery
and is closely linked to nutrient availability and cell
growth (Campbell and White 2014). RNA Pol II and a set
of auxiliary general (or basal) transcription factors are re-
sponsible for the expression of all protein-encoding genes
and a diverse group of regulatory noncoding RNA genes
(Sainsbury et al. 2015). The differential regulation of
RNA Pol II initiation and elongation is fundamental to
gene expression during development, homeostasis, and
disease. Sequence-specific DNA-binding transcription
factors thatbindpromoters andenhancerelements impose
gene selectivity on RNA Pol II transcription (Levine et al.
2014; Koster et al. 2015). These transcription factors func-
tion through the recruitment of transcriptional corepres-
sors or coactivators to regulatory DNA elements. Many
of these transcriptional coregulators target the structure
of chromatin to either enable or block gene transcription.
The packaging of eukaryotic genomic DNA into chro-
matin constitutes a major level of gene transcription con-
trol (Koster et al. 2015; Venkatesh and Workman 2015;
Allis and Jenuwein 2016). The nucleosome is the basic re-
peat unit of eukaryotic chromatin, comprising 147 base
pairs (bp) of DNA wrapped tightly around a protein
core formed by two copies each of the core histones:
H2A, H2B, H3, and H4 (Luger et al. 1997). Put simply, nu-
cleosomes create a barrier to the accessibility of genes
and regulatory DNA sequences, thereby controlling
Table 2. Metabolites involved in chromatin regulation
Metabolite Synthesized by  Synthesized from Cellular processes 
Acetyl-CoA ATP-citrate lyase (ACLY) 
ACSS2 
ACSS1  
PDC  
Ketothiolases  
Citrate 
Acetate 
Acetate 
Pyruvate 
β-ketoacyl CoA 
TCA cycle, protein acetylaon, ketone 
body synthesis, fay acid synthesis, 
steroid synthesis,  
α-ketoglutarate 
(αKG) 
Isocitrate dehydrogenases (IDH) 
Aminotransferases 
Glutamate dehydrogenase (GDH) 
Isocitrate 
Glutamate 
Glutamate 
TCA cycle, demethylaon by αKG-
dependent dioxygenases, amino acid 
catabolism 
β-hydroxybutyrate 
(βOHB) 
β-hydroxybutyrate dehydrogenase Acetoacetate Ketone body metabolism, histone lysine  
β-hydroxybutyrylaon. Inhibitor of class I 
and IIa HDACs 
Butyrate Bacterial fermentaon Dietary 
components 
Inhibitor of class I and IIa HDACs, fay 
acid oxidaon, histone lysine 
butyrylaon (probably via butyryl-CoA) 
Crotonyl-CoA Glutaryl-CoA dehydrogenase 
ACADS 
ACSS2 
Glutaryl-CoA 
Butyryl-CoA 
Croton 
Lysine and tryptophan catabolism, β-
oxidaon 
FAD+ FAD synthetase (FLAD1) 
Reducing enzymes 
FMN 
FADH2 
Electron acceptor in redox reacons 
Demethylaon by LSD1 and LSD2 
Fumarate Succinate dehydrogenase (SDH) Succinate  TCA cycle, inhibitor of  αKG dependent 
dioxygenases 
2-hydroxyglutarate 
(R-2HG) 
Mutated IDH1 and IDH2 Isocitrate Inhibitor of  αKG dependent 
dioxygenases 
NAD+ NMN adenyltransferase (NMNAT) 
NAD+ synthetase (NADSYN) 
Reducing enzymes 
NMN 
NAAD 
NADH 
Hydrogen acceptor for dehydrogenases, 
Deacetylaon/deacylaon by sirtuins, 
ADP-ribosylaon by PARPs, 
Cyclic-ADP-ribose synthesis 
Niconamide 
(NAM) 
Poly ADP-ribose polymerases (PARP) 
Sirtuins (SIRT) 
Cyclic ADP-ribose (cADPR) synthases 
NAD+ 
NAD+ 
NAD+ 
Inhibitor of sirtuins, NAD+ salvage 
pathway 
Niconamide 
mononucleode 
(NMN) 
NAM phosphoribosyltransferase 
(NAMPT) 
NAM NAD+ salvage pathway 
S-adenosyl-
homocysteine 
(SAH) 
Methyltransferases SAM Inhibitor of methyltransferases 
S-adenosyl-
methionine (SAM) 
Methionine adenosyltransferases 
(MAT) 
ATP and 
methionine 
Methyl donor in methylaon reacons 
Succinate Succinyl CoA synthetase (SCS) 
αKG dependent dioxygenases 
Succinyl-CoA 
Methylated 
proteins and DNA 
TCA cycle, inhibitor of  αKG dependent 
dioxygenases 
List of the main metabolites involved in chromatin regulation. The second column indicates the process or key enzymes involved in
their production. The third column provides the main substrates used by the enzymes in the second column. Key words in the last
column indicate the cellular processes in which these metabolites are involved. Some abbreviations of enzymes are in Table 1. (FMN)
Flavin mononucleotide; (NAAD) nicotinic acid adenine dinucleotide.
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transcription. Consequently, by mediating the assembly,
sliding, restructuring, or ejection of nucleosomes,ATP-de-
pendent chromatin remodeling factors play a central role
in the regulation of gene expression (Venkatesh andWork-
man 2015). A distinct biochemical mechanism involves a
plethora ofPTMsof specific residueswithin thehistoneN-
terminal tails, which protrude from the nucleosome.
These modifications, including acetylation, methylation,
andphosphorylation, canmodulate the folding of the chro-
matin fiber or direct recruitment of regulatory proteins,
suchas transcription factors orotherchromatin regulators.
Transcriptional activity is intimately associated with
specific histone modifications (Patel and Wang 2013;
Zentner and Henikoff 2013; Swygert and Peterson 2014;
Allis and Jenuwein 2016). For example, acetylation of his-
tone H3 Lys27 (H3K27ac) marks active genes, whereas tri-
methylation of the same residue (H3K27me3) by the
Polycomb-repressive complex 2 (PRC2) leads to gene si-
lencing. Histone acetylation is generally associated with
active chromatin irrespective of which residue is modi-
fied. In contrast, the consequences of histonemethylation
are determined by the specific residue that is targeted or
even by the number of methyl groups added. Methylation
of H3K4, H3K36, or H3K79 is usually associated with ac-
tive transcription, whereas methylation of H3K9, H3K20,
or H3K27 marks transcriptionally repressed chromatin.
The recognition of histone PTMs by specific protein do-
mains is important for the formation of repressive or ac-
tive chromatin structures (Allis and Jenuwein 2016). For
example, the bromodomain acts as an acetyl-lysine-bind-
ing module, enhancing the recruitment of transcription
factors to chromatin. In contrast, the binding of the chro-
modomain of HP1 to H3K9me3 mediates heterochroma-
tin formation. It is important to note that chromatin
PTMs are dynamic; they are continuously placed and re-
moved by antagonizing sets of enzymes. Moreover, en-
zymes that modify histones also target and modulate
the activity of transcription factors (and other proteins).
Thus, caution should be used in equating the regulatory
role of a chromatin-modifying enzyme to a particular his-
tone PTM. Reflecting their key role in gene control, can-
cer genome sequencing studies revealed that chromatin-
modulating enzymes are frequently mutated in human
cancers (Laugesen and Helin 2014; Masliah-Planchon
et al. 2015; Morgan and Shilatifard 2015).
The DNA itself is also subject to modifications. In par-
ticular, methylation of cytosines (5-methylcytosine
[5mC]) by DNA methyltransferases (DNMTs) within
CpG islands in vertebrate genomes is linked tightly to
gene transcription (Schübeler 2015). CpG islands, the
most common promoter motifs in vertebrate genomes,
are GC-rich DNA sequences of several hundreds of base
pairs that are highly enriched for CpG dinucleotides.
CpG promoters are stably silenced by a high level of CpG
methylation. Many tumors are characterized by aberrant
CpG island methylation, which is referred to as a CpG is-
land methylator phenotype (Toyota and Issa 1999). DNA
methylation can be reversed passively (i.e., lost during sev-
eral rounds ofDNAreplication) or removed actively by the
ten-eleven translocation (TET) enzymes (Schübeler 2015;
Rasmussen and Helin 2016). TET enzymes oxidize 5mC
to 5-hydroxymethylcytosine (5hmC), which is the first
step in active DNA demethylation. Moreover, 5hmC
may function as a chromatin mark, but more research on
this potential function is needed.
In summary, sequence-specific transcription factors
provide gene specificity but act through the recruitment
of coregulators. Many of these coregulators function by
modulating chromatin structure; e.g., by opening it up
to allow DNA access to other transcriptional regulators.
Furthermore, histone PTMs can be recognized by selec-
tive regulatory proteins, including basal transcription fac-
tors or other histone-modulating enzymes. This way,
chromatin modifications can lead to a cascade of events
that either promote or block gene expression.
The interface between metabolism and gene expression
Whereas some aspects of the coordination of metabolism
and gene expression are well understood, others are still
largely speculative. Specialized transcription factors are
activated in response to changes in metabolism and elicit
the appropriate changes in gene expression (Fig. 1). For ex-
ample, unactivated, the transcription factor sterol regula-
tory element-binding protein (SREBP) is anchored to the
membrane of the endoplasmatic reticulum. When sterol
levels become low, SREBP is cleaved, and an N-terminal
transcriptionally active version is released and trans-
locates to the nucleus. Here, it activates genes encoding
sterol biosynthetic enzymes (Raghow et al. 2008). Like-
wise, nuclear receptors mediate transcriptional responses
to steroid hormones, thyroid hormone, and vitamins A
Nutrients & Vitamins
Metabolites Metabolic Enzymes
Extracellular 
Signals
Signal Transduction
Mitochondrion
NucleusCytoplasm
METABOLIC STATE
Cofactors
Gene Expression
Control
Active Repressed
Chromatin
Modulators ME
ME
TCA
cycle
Nuclear Receptors 
Hormones
Transcriptional control of metabolism
Figure 1. The interface between metabolism and transcription.
Specialized transcription factors that are activated by metabolic
sensors or extracellular signals, such as hormones, direct a tran-
scriptional response to changes in metabolic state. In addition,
key components of intermediary metabolism are cofactors or
cosubstrates of chromatin-modifying enzymes. Therefore, chang-
es in cofactor availability may affect chromatin structure and
gene expression. Finally, specialized metabolic enzymes (MEs)
do double duty as regulators of chromatin and transcription. Fre-
quently, cytoplasmic–nuclear partitioning is used as a regulatory
mechanism to link metabolic state to transcriptional outcomes.
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and D (Evans andMangelsdorf 2014). Thus, by controlling
the expression of various metabolic enzymes, transcrip-
tion factors such as SREBP and nuclear receptors regulate
the metabolic state of cells.
Eukaryotic cells harbor two kinases that are specifically
adapted to sense metabolic state. The mechanistic target
of rapamycin (mTOR) is a kinase that has a fundamental
role in integrating both intracellular and extracellular sig-
nals (Kennedy and Lamming 2016). mTOR is activated in
response to nutrients or growth factors and serves as a cen-
tral regulator of cell homeostasis and growth. The AMP-
activated protein kinase (AMPK) system acts as a sensor
of cellular energy status (Burkewitz et al. 2014). AMPK
is activated by an increase in the cellular AMP/ATP ratio
and then switches on catabolic pathways that generate
ATP while repressing ATP-consuming anabolic process-
es. Current knowledge indicates that the mTOR and
AMPK signaling pathways act predominantly at a post-
transcriptional level. However, AMPK phosphorylates
histone H2B to activate gene transcription in response
to cellular stress (Bungard et al. 2010).
Virtually all enzymes thatmodify chromatin rely on co-
factors or substrates that are core metabolites of interme-
diary metabolism (Fig. 2). These metabolites may thus
provide an alternate way to coordinate gene regulation
with metabolic state. Histone acetyltransferases (HATs)
use acetyl-CoA as an acetyl donor (Fig. 3A). HATs are
also called lysine acetyltransferases (KATs) to reflect
that they acetylatemany other proteins in addition to his-
tones. Histone acetylation is associated with active chro-
matin and is removed by histone deacetylases (HDACs;
also called lysine deacetylases [KDACs]) that are part of
transcriptional repressor complexes. Most HDACs re-
quire Zn2+ and use water as nucleophile in the deacetyla-
tion reaction. The sirtuins (class III HDACs), however,
consume NAD+ as a cosubstrate, converting it into NAM
and O-acetyl-ADP-ribose (Fig. 3A).
Histone methylation is mediated by lysine methyl-
transferases (KMTs; also called histone methyltransfer-
ases [HMTs]) and protein arginine methyltransferases
(PRMTs). Both classes of enzymes use S-adenosylmethio-
nine (SAM) as methyl donor (Figs. 2, 4A). SAM is also the
methyl donor for DNMTs thatmethylate CpGs. Removal
ofmethyl groups from lysine residues in histones involves
two different classes of lysine demethylases (KDMs; also
called histone demethylases [HDMs]). Demethylation by
the first KDM identified, LSD1 (lysine-specific demethy-
lase 1) (Shi et al. 2004), or its paralog, LSD2, requires the
reduction of Flavin adenine dinucleotide (FAD). The
Jumonji C (JmjC) domain-containing KDMs catalyze a
different demethylation reaction that requires α-keto-
glutarate (αKG), O2, and Fe(II) (Walport et al. 2012).
Me
chromatin
modifying enzymes 
chromatin 
Ac-CoA
sirtuinPARP HATDNMT
KMT
PRMT
TET HDAC
Ac-CoA
Trp cit
B-vitamins amino acidsglucose
Gln
NA
nutrients
cofactors & 
cosubstrates
pyr3-PG
β-
ox
id.
βOHB
ketone bodies
SAM
Met
Ser
SAH
THF
Gly
vit B12
vit B2
folate
cit
NAD+
metabolites
Mal-CoA
fatty acids
hCys
Ser
Gly
pyr
glucose
CH2-THF
CH3-THF
CH2-THF
folate
cycle
Met
cycle
Gly
cleavage
10-fTHF
purines
Glu
PEP
cit
αKG
icitsuc
fum TCA
cycle
3-P-PYR
3-P-Ser
glycolysis
αKG
Glu
Se
r b
io
sy
nt
he
si
s
lac
Acet.
ar Ac
CG
Me
but
electron carrier
ketone body
B-vitamin
amino acid
carboxylic acid
fatty acid
NAM
R-2HG
αKG
suc
fum
JMJC
icit
R-2HG
αKG
suc
fum
FAD
LSD1/2
vit B2 NR
HCO2 HCO2
fatty acids
Figure 2. Cofactors and cosubstrates of intermediary metabolism that are involved in chromatin regulation. Note that the schematic
representation of key metabolic pathways is simplified. To emphasize the steps discussed in the text, we omittedmultiple steps and con-
nections between pathways. (3-PG) 3-phosphoglycerate; (3-P-PYR) 3-phosphopyruvate; (3-P-Ser) 3-phosphoserine; (THF) tetrahydrofolate;
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sylhomocysteine; (suc) succinate; (TET) TET DNA demethylase; (Trp) tryptophan;(vit) vitamin.
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Hydroxylation of 5meC in DNA by TET enzymes in-
volves a similar reaction. Collectively, these demethy-
lases are known as αKG-dependent dioxygenases. As we
discuss below, fluctuations in metabolites that function
as cofactors for chromatin modifications may provide a
mechanism to couple a transcriptional response to chang-
es in nutrient status.
Finally, a small but increasing number of metabolic en-
zymes have been identified that are directly involved in
chromatin and transcription control. These observations
suggest that thesedual-function enzymesmight act as sen-
sors of metabolic state and provide a novel connection be-
tween metabolism and gene control (Fig. 1). Interestingly,
gene regulation bymetabolic enzymes involves a wide va-
riety of molecular mechanisms, sometimes independent
of enzymatic activity. Thus, the control of metabolism
by transcription factors, which determine the expression
of key metabolic enzymes, is balanced by metabolites
used by chromatin-modulating enzymes or metabolic en-
zymes that function as transcriptional coregulators.
Changes in acetyl-CoA metabolism influence chromatin
structure
Histone acetylation modulates chromatin structure by
neutralizing the positive charge of the lysine residues,
thus weakening the electrostatic interactions between
DNA and histones and between adjacent nucleosomes
(Shogren-Knaak et al. 2006). This creates a more open,
accessible chromatin structure that is conducive to tran-
scription. In addition, histone acetylation creates binding
sites recognized by bromodomain-containing regulators,
which typically promote gene activation (Filippakopoulos
and Knapp 2014). The acetyl donor for histone acetyla-
tion, acetyl-CoA, is a centralmetabolite used in a plethora
of cellular reactions (Fig. 2, 3A,B). It plays a key role in the
TCA cycle, fueling oxidation for energy production in the
mitochondria, but is also used in anabolic pathways for
cellular growth. Cells contain two separate pools of ace-
tyl-CoA: a mitochondrial pool and a combined nuclear
and cytosolic pool, which is united by free diffusion of ace-
tyl-CoA through the nuclear pores. Glycolysis and degra-
dation of specific amino acids, such as alanine or serine,
yield pyruvate, which can be oxidized into acetyl-CoA
by the mitochondrial pyruvate dehydrogenase complex
(PDC). In addition, β-oxidation of fatty acids and ketone
bodies also contributes to the mitochondrial acetyl-CoA
pool. Apart from oxidation in the TCA cycle, acetyl-
CoA is also used for cellular processes outside the mito-
chondrion. These include the biosynthesis of fatty acids
and sterols and also acetylation of proteins, including his-
tones. The inner mitochondrial membrane does not have
a transporter for acetyl-CoA; therefore, acetyl units are
transported into the cytosol as citrate. Subsequently,
ATP-citrate lyase (ACLY) will cleave citrate into acetyl-
CoA and oxaloacetate at the expense of ATP and CoA. Al-
ternatively, cytosolic acetyl-CoA can be produced from
acetate by acyl-CoA synthetase short chain family mem-
ber 2 (ACSS2). In older literature, ACSS2 is also known as
acetyl-CoA synthetase 1 (AceCS1). Note that whereas ac-
etate is a major biosynthetic substrate in yeast, it normal-
ly plays only a minor role in mammalian cells (Menzies
et al. 2016).
Cellular acetyl-CoA levels fluctuate in response to a
number of factors, which include nutrient availability,
the circadian clock, development, and aging. Fasting or ca-
loric restriction leads to a drop of acetyl-CoA levels in
heart, muscle, and liver tissue (Hebert et al. 2013; Mariño
et al. 2014). Acetyl-CoA levels have even been shown to
vary during embryonic development and aging (Tsuchiya
et al. 2014; Peleg et al. 2016). These observations raise the
question of whether changes in acetyl-CoA levels may
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have an impact on chromatin acetylation and transcrip-
tion. Indeed, reduction of acetyl-CoA production by
siRNA-mediated knockdown of either ACLY or PDC re-
sults in hypoacetylation of histones in mammalian cells
(Wellen et al. 2009; Sutendra et al. 2014). In contrast,
knockdown of ACSS2 has no effect on global histone acet-
ylation, reflecting that acetate is normally not amajor bio-
synthetic substrate in mammalian cells. However, it
should be kept in mind that, under certain conditions
(e.g., in cancer cells), acetate can become an important
source of acetyl-CoA.
Studies in yeast provided the first physiological evi-
dence for the close interconnectivity between nutrient
availability and histone acetylation. Yeast cells grown un-
der limited glucose conditions oscillate through three
metabolic phases—the so-called yeast metabolic cycle
(YMC) (Tu et al. 2005). The level of acetyl-CoA oscillates
with the same periodicity as the YMCand peaks in the ox-
idative phase, which is characterized by high oxygen con-
sumption and the induction of genes involved in growth.
The periodicity of acetyl-CoA levels ismirrored by the lev-
els of genome-wide histone acetylation in a HAT-depen-
dent manner (Cai et al. 2011). The higher level of
chromatin acetylation is accompanied by the induction
of ∼1000 growth-related genes. Moreover, increased glu-
cose availability in stationary yeast cells leads to higher
levels of acetyl-CoA synthesis and global histone acetyla-
tion (Friis et al. 2009). The observation that availability of
acetyl-CoA determines the level of histone acetylation
suggests that HATs are substrate-limited enzymes. A re-
lated connection between fluctuating acetyl-CoA levels
and histone acetylation has been made in mammalian
cells. In various cancer cell lines, high levels of glucose
drive increasing amounts of acetyl-CoA, accompanied by
a boost in histone acetylation (Lee et al. 2014). A key ques-
tion is whether fluctuations in acetyl-CoA trigger a specif-
ic transcriptional response. The studies on the YMC
suggest that fluctuations in acetyl-CoA can indeed cause
specific effects on gene expression. Selectivity may result
from the gene-specific recruitment of HATs that have a
differential response to acetyl-CoA concentrations.
Nuclear synthesis of acetyl-CoA
Acetyl-CoA can diffuse freely through the nuclear pores;
thus, at first glance, nuclear synthesis would not be need-
ed. However, multiple enzymes involved in acetyl-CoA
synthesis, including ACSS2 and ACLY, have been ob-
served in the nucleus (Takahashi et al. 2006; Wellen et
al. 2009; Ariyannur et al. 2010; Comerford et al. 2014).
Moreover, it has been reported that a functional PDC
can translocate from themitochondria to the nucleus dur-
ing S phase of the cell cycle in response to serum, epider-
mal growth factor, or mitochondrial stress (Sutendra et al.
2014). Unexpectedly, nuclear translocation of the PDC is
required for normal acetylation of histone H3 during S
phase (Sutendra et al. 2014). Although nuclear levels of
acetyl-CoA were not determined, these observations
suggest that histone acetylation may depend on locally
produced acetyl-CoA by the PDC. Pyruvate, the end prod-
uct of the glycolysis, fuels the PDC. However, there is no
evidence for nuclear glycolysis, although many glycolytic
enzymes have been observed in the nucleus (Boukouris
et al. 2016). For some of those, like glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), it seems clear that they
are not enzymatically active in the nucleus but perform
moonlighting functions (see below). Pyruvate kinase
(PK) has been reported in the nucleus and might produce
pyruvate from phosphoenolpyruvate (PEP). Alternatively,
pyruvate might diffuse into the nucleus from the cytosol
and then serve as a substrate for the PDC. In summary, lo-
calized acetyl-CoA production by ACSS2, ACLY, and the
PDCmight occur at specific locations in the nucleus, pos-
sibly creating a hub of HAT activity.
Acetyl-CoA dynamics and chromatin acetylation
in cancer cells
Cell differentiation or oncogenic transformation can have
a major impact on intermediary metabolism. Typical dif-
ferentiated cells have a low rate of glycolysis, the conver-
sion of glucose into pyruvate. Pyruvate is then oxidized in
the mitochondrial TCA cycle to generate ATP. Most can-
cer cells, however, are characterized by a high rate of gly-
colysis followed by lactic acid fermentation in the cytosol.
In noncancerous cells, lactate is normally generated
only under low-oxygen conditions. Therefore, the cellular
production of lactate in the presence of oxygen is termed
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“aerobic glycolysis.” The shift in cancer cells from mito-
chondrial oxidative respiration to aerobic glycolysis is
called theWarburg effect. Compared with oxidative respi-
ration in mitochondria, aerobic glycolysis is a very ineffi-
cient route for ATP production. The conversion of glucose
into lactate yields only two ATP molecules per glucose
molecule, while the complete oxidation of glucose into
CO2 andH2Oyields∼32ATPmolecules permolecule glu-
cose. The advantage for cancer (and other fast-proliferat-
ing cells) is that the glycolysis intermediates provide the
building blocks for anabolic biosynthesis to support cell
growth and proliferation. Similar metabolic reprogram-
ming occurs during animal development. For example,
during the ∼4 d of Drosophila larval development, a
switch to aerobic glycolysis supports an almost 200-fold
increase in body mass (Tennessen et al. 2011, 2014).
This change in metabolism is directed by the fly estro-
gen-related receptor, which functions as a transcriptional
master regulator of development (Tennessen et al. 2011,
2014). Thus, developmental progression andmetabolic re-
programming are tightly coupled. In summary, ametabol-
ic switch to aerobic glycolysis can be a physiological
response to enable growth but can also be part of oncogen-
ic transformation.
In spite of theWarburg effect in cancer cells, under con-
ditions of sufficient oxygen (normoxia), the majority of
acetyl-CoA used for protein acetylation is still glucose de-
rived (Evertts et al. 2013; Schug et al. 2015). A fraction of
the pyruvate produced by glycolysis is shuttled into the
mitochondrial TCA cycle and used for citrate production.
In addition, tumor cells often activate ACLY via the Akt
protein kinase, further stimulating acetyl-CoA produc-
tion from glucose (Lee et al. 2014). However, the hypoxic
conditions in solid tumors lead to an increased conversion
of glucose to lactate as the mitochondria become oxygen-
deprived. This switch is enhanced by the hypoxia-induced
transcription factor 1 (HIF1), which activates glycolytic
enzymes and induces pyruvate dehydrogenase kinase
(PDK), which suppresses the TCA cycle and respiration
(Kim et al. 2006; Papandreou et al. 2006). Under these con-
ditions, cancer cells often use exogenous acetate as an al-
ternate carbon source for acetyl-CoA production by
ACSS2 (Comerford et al. 2014; Mashimo et al. 2014;
Schug et al. 2015). Although acetate is a low-concentra-
tion serum metabolite, it has been suggested that the ad-
aptation of a tumor cell toward a suboptimal carbon
source might give it a competitive advantage over normal
cells (Comerford et al. 2014).
The dynamics of histone PTMs, including acetylation,
are typically analyzed in the context of gene regulation.
However, bulk levels of chromatin PTMs can vary consid-
erably between different tissues or developmental stages
or in cancer cells. In particular, low levels of global histone
acetylation or methylation are associated with more ag-
gressive cancers and poor patient outcome (Kurdistani
2011, 2014; Greer and Shi 2012). These global changes
are difficult to reconcile with gene-specific transcription
programs. Given the high abundance of histones, howev-
er, chromatin acetylation may have effects beyond gene
control. Acetylated histones might function as a storage
site for acetate to be released by HDACs when the need
arises (Kurdistani 2014). Acetatemay then be used for ace-
tyl-CoA production (Comerford et al. 2014). Kurdistani
and coworkers (McBrian et al. 2013; Kurdistani 2014)
made a compelling argument for histone acetylation as a
regulator of intracellular pH. Lowering of the intracellular
pH results in global deacetylation of histones with con-
comitant secretion of acetate anions and protons into
the extracellular environment. Conversely, a higher pH
results in increased histone acetylation and reduced coex-
port of acetate and protons. These observations suggest
that chromatin function is not limited to the storage and
expression of genetic information. Rather, chromatin
may play an integral role in the control of cellular physiol-
ogy by acting as rheostat of carbon flux and cellular pH. Fi-
nally, acetate consumption might be an adaptation of
tumor cells to increased acetate secretion by surrounding
stromal cells, which is a response to acidification due to
lactate produced by cancer cells.
The role of acetyl-CoA in stem cell pluripotency
There is an increasing appreciation that metabolic state
influences whether a stem cell will self-renew or undergo
differentiation (Ito and Suda 2014; Ryall et al. 2015a).
Thus, metabolic pathways may provide cues to gene ex-
pression programs that control cell fate. Pluripotent
stem cells (PSCs) are characterized by an open chromatin
structure, which is reflected in a low abundance of hetero-
chromatin and enrichment of active chromatin modi-
fications, such as histone H3 and H4 acetylation and
H3K4me3 (Gaspar-Maia et al. 2011). To establish and
maintain these histone modifications, PSCs have a meta-
bolic profile that is distinct frommore differentiated cells.
One of the characteristics of both human embryonic
stem cells (hESCs) and mouse ESCs (mESCs) is an elevat-
ed level of acetyl-CoA, which drops upon differentiation
(Wang et al. 2009; Moussaieff et al. 2015). However, there
are important differences between the two species.
mESCs, but not hESCs, are dependent on a threonine ca-
tabolism program driven by the enzyme threonine dehy-
drogenase. This leads to higher levels of acetyl-CoA and
fuels the one-carbon cycle via the generation of glycine
(Wang et al. 2009). Humans lack this enzyme, and hESCs
acquire high levels of acetyl-CoA from aerobic glycolysis
and low levels of oxidative phosphorylation (Moussaieff
et al. 2015). Instead of being oxidized in the TCA cycle,
mitochondrial acetyl-CoA is exported to the cytosol as
citrate. This somewhat resembles the Warburg effect in
cancer cells, but there is an intriguing distinction. Many
cancer cells are killed by redirection of pyruvate from lac-
tate to acetyl-CoA by inhibition of PDK, which is an in-
hibitor of the PDC (Bonnet et al. 2007). In contrast,
inhibition of PDK in hESCs increases pluripotency with-
out affecting viability (Moussaieff et al. 2015). This sug-
gests that, in hESCs, aerobic glycolysis is required for
maintenance of sufficient acetyl-CoA levels, while, in
cancer cells, the primary function is generating anabolic
building blocks to fuel proliferation. High levels of
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glycolysis-derived acetyl-CoA in ESCs may serve to en-
sure high levels of histone acetylation to maintain chro-
matin plasticity, enabling pluripotency (Moussaieff et al.
2015). However, cell differentiation does not always corre-
late with a decrease in acetyl-CoA and histone acetyla-
tion. For example, histone acetylation increases upon
differentiation of preadipocytes into adipocytes, which re-
quires the activity of ACLY (Wellen et al. 2009).
Histone acylation beyond acetylation
The mass spectrometry revolution of the last decade en-
abled the discovery of new histone PTMs, including a
range of acylation reactions other than acetylation (e.g.,
see Tan et al. 2011; Hirschey and Zhao 2015). These in-
clude propionylation, butyrylation, β-hydroxybutyryla-
tion, crotonylation, malonylation, and succinylation of
lysine residues within histones (Fig. 3C). Similar to acety-
lation, the acyl groups are most likely donated by the cor-
responding acyl-CoA. Exciting recent studies suggest that
these novel histone acylations can play a major role in
metabolic regulation of gene expression.
Prolonged fasting, restricted intake of carbohydrates, or
untreated diabetes mellitus type 1 induces the formation
of ketone bodies in the liver, where fatty acids are broken
down for energy production. Ketone bodies (acetoacetate,
β-hydroxybutyrate [βOHB], and acetone) are secreted and
serve as a source of energy in extrahepatic tissues, such
as the heart, brain, or muscles. In these tissues, ketone
bodies are converted into acetyl-CoA, which then is
oxidized in the TCA cycle for ATP production. βOHB syn-
thesis in the hepaticmitochondria starts with the conden-
sation of acetoacetate out of two acetyl-CoA molecules
originating from fatty acid or amino acid catabolism.
Next, βOHB dehydrogenase reduces acetoacetate into
βOHB, which is released into the bloodstream. During
fasting, βOHB concentrations can range from 6–8 mM in
healthy individuals to up to 25mM during diabetic ketoa-
cidosis (Laffel 1999). In addition to serving as a source of
energy, βOHB may also leave its mark on chromatin (Shi-
mazu et al. 2013; Xie et al. 2016).
βOHB, which is structurally related to the well-known
HDAC inhibitor butyrate, can inhibit class I and IIa
HDACs (Figs. 2, 3A; Shimazu et al. 2013). Both caloric
restriction of mice and direct administration of βOHB
resulted in enhanced global histone acetylation, consis-
tent with decreased HDAC activity. Studies in cells pro-
vided additional evidence for the notion that βOHB can
change gene expression through inhibition of HDAC1
and HDACII (Shimazu et al. 2013). The connection with
the FOXO3a transcription factors suggests a molecular
route to gene selectivity. An alternative scenario centers
on the identification of lysine β-hydroxybutyrylation
(Kbhb) as a novel histone PTM (Xie et al. 2016). Xie et al.
(2016) observed that starvation ofmice or treatment of tis-
sue culture cells with βOHB resulted in a 10-fold to 40-fold
increase of histone Kbhb but onlymarginal changes in his-
tone acetylation. β-Hydroxybutyrylation occurs on 44 his-
tone residues, including many that are also targets for
acetylation or methylation, such as H3K9. Like H3K9ac,
H3K9bhbwas found to be associatedwith active gene tran-
scription. Thus, histone Kbhb provides a chromatin mark
directly connected to metabolic state, most likely via the
synthesis of βOHB-CoA. A key question that now needs
to be addressed is how this modification may direct adap-
tive gene transcription programs; e.g., through collabora-
tion with specific transcription factors.
Butyrate is amajormetabolite produced by bacterial fer-
mentation of dietary fiber in the colon. Butyrate is an im-
portant food source for colonocytes, the epithelial cells
that line the colon, which use it to fuel β-oxidation for en-
ergy production (Guilloteau et al. 2010). Excess butyrate is
passed to the liver via the portal vein.However, concentra-
tions in the peripheral circulation are very low, making a
direct effect of butyrate via blood circulation unlikely
(Guilloteau et al. 2010). Butyrate is of particular interest
because it can inhibit the growth of cancerous, but not
noncancerous, colonocytes (Lupton 2004). Butyrate has
long been used as a cell-differentiating agent and is a
well-established inhibitor of class I and class IIa HDACs
(Figs. 2, 3A; Boffa et al. 1978, Sealy and Chalkley 1978).
In colonocytes, butyrate can boost histone acetylation by
inhibition of HDACs or by increasing acetyl-CoA levels
to stimulate HAT activity (Donohoe et al. 2012). Interest-
ingly, the metabolic state of the cell can determine which
pathway is dominant. In cancerous colonocytes (which fa-
vor glycolysis over mitochondrial oxidation), only limited
amounts of butyrate are metabolized, leading to its accu-
mulation and HDAC inhibition. In noncancerous colono-
cytes, butyrate is metabolized into acetyl-CoA, which
stimulates HAT activity. The inhibition of HDACs or
stimulation of HATs may lead to different patterns of
gene expression and physiological outcomes (Donohoe
et al. 2012). These results suggest that metabolic state
(i.e., the Warburg effect) can determine the effect of buty-
rate on chromatin acetylation and cell proliferation.
However, there is more to butyrate than its effects on
histone acetylation. Histones have been found to be
butyrylated on multiple lysines (Chen et al. 2007; Gou-
darzi et al. 2016). Both histone lysine butyrylation (Kbu)
and lysine crotonylation (Kcro) are associated with active
transcription (Tan et al. 2011). In vitro, both butyrylation
and crotonylation can be catalyzed by the HATs p300 and
CBP (Chen et al. 2007; Sabari et al. 2015; Goudarzi et al.
2016).Moreover, knockdown experiments support the no-
tion that p300/CBP mediate crotonylation in cells (Sabari
et al. 2015). Reducing the nucleocytosolic amount of ace-
tyl-CoA by depletion of ACLY or PDC not only decreases
H3K18ac but also increases H3K18cr. This indicates that
acetyl-CoA and crotonyl-CoA competewith each other in
p300/CBP-catalyzed reactions and suggests that the rela-
tive availability of short chain fatty acids may modulate
chromatin acylation status.
This raises the following question: Do different acyla-
tion marks lead to different transcriptional outcomes?
Present evidence indicates that all acylation marks are
associated with active chromatin. Acetylation, butyryla-
tion, β-hydroxybutyrylation, and crotonylation will all
neutralize the positive charge of the ε-amino group of
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lysine and may thus create a more open chromatin struc-
ture. Alternatively, different forms of acylationmay affect
the histone binding of regulatory factors. Bromodomains
act as an acetyl-lysine-binding module (Dhalluin et al.
1999; Sanchez and Zhou 2009). Due to the larger size of
the butyryl group, bromodomains have a >10-fold lower
affinity for butyrylated lysines than acetylated lysines
(Goudarzi et al. 2016; Li et al. 2016). Recently, YEATS do-
mains have been proposed as crotonylated lysine-recog-
nizing modules, as they have a twofold to threefold
lower dissociation constant (Kd) for Kcr than Kac (Li
et al. 2016). It remains to be determinedwhether these dif-
ferences in binding affinities for acylated histones are rel-
evant for gene regulation in vivo.
NAD in chromatin regulation
NAD+ plays a crucial role in the intermediarymetabolism
of all living organism. As an enzymatic cofactor, NAD+ is
a key electron carrier in a plethora of cellular redox reac-
tions. As a cosubstrate, NAD+ is consumed in sirtuin-cat-
alyzed deacetylation reactions, yielding NAM and O-
acetyl-ADP-ribose (Figs. 2, 3A). Two additional classes
of enzymes metabolize NAD+ into NAM. These are
poly-ADP-ribose polymerases (PARPs) and cyclic ADP-ri-
bose (cADPR) synthases. The relatively unknown cADPR
synthases (CD38 and its relative, CD157) produce the sec-
ondary messenger cADPR, which is involved in Ca2+ sig-
naling (Cantó et al. 2015).
Sirtuins are protein deacetylases (and deacylases) con-
served from bacteria to humans (Bheda et al. 2016). Sir-
tuins have been implicated in the regulation of circadian
rhythm, mitochondrial metabolism, aging, and cancer
(Imai and Guarente 2014; Chalkiadaki and Guarente
2015). There are seven mammalian sirtuins, which are lo-
calized in the mitochondria (SIRT3, SIRT4, and SIRT5),
the nucleus (SIRT1, SIRT6, and SIRT7), or both the cyto-
plasm and nucleus (SIRT2). All nuclear sirtuins can deace-
tylate histones, but numerous additional substrates have
been identified, including transcriptional factors, DNA re-
pair proteins, and metabolic enzymes (Chalkiadaki and
Guarente 2015; Bheda et al. 2016). Some sirtuins can
also remove acyl modifications from histones. However,
the in vivo relevance of this activity remains to be deter-
mined. PARPs transfer ADP-ribose subunits from NAD+
to target proteins, including itself and histones (PARyla-
tion). The PARP family is composed of 17 members that
are involved in processes such asDNA repair, gene expres-
sion, and RNA regulation (Gibson and Kraus 2012; Bock
et al. 2015). PARylation can modulate protein functions
in several ways, including inhibition of protein–protein
interaction or protein–nucleic acid interaction. Targets
for PARylation include sequence-specific transcription
factors, elongation factors, and histone-modifying en-
zymes. Studies in Drosophila and mammalian cells indi-
cate that chromatin-associated PARylation correlates
with transcribed genes and promotes elongation (Tulin
and Spradling 2003, Krishnakumar et al. 2008, Petesch
and Lis 2012, Gibson et al. 2016).
Diet, NAD+ metabolism, and protein deacetylation
by sirtuins
One reason sirtuins have been the focus of intense study is
the notion that they are key mediators of life span regula-
tion in response to dietary changes. A central aspect of
this theory is that NAD+ (and NADH) levels change based
on diet and aging. NAD+ can be synthesized de novo from
diverse dietary sources or regenerated from NAM via the
salvage pathway (Fig. 3D; Cantó et al. 2015; Verdin 2015).
Dietary sources include tryptophan or precursor mole-
cules such as NAM riboside (NR), nicotinic acid (NA),
and NAM. NR and NAM are collectively known as vita-
min B3, and their dietary deficiency causes pellagra.
NAD+ synthesis from tryptophan is inefficient because
the intermediate 2-amino-3-carboxymuconate-6-semial-
dehyde (ACMS) is shuttled into the glutarate pathway
by the enzyme ACMS decarboxylase (ACMSD), which
leads to its complete oxidation into CO2 and H2O in the
TCA cycle. NAD+ can be formed from tryptophan only if
the amount of ACMS exceeds the enzymatic capacity of
ACMSD.
The first and rate-limiting step in the salvage pathway is
the conversion of NAM into NAM mononucleotide
(NMN) by NAM phosphoribosyltransferase (NAMPT).
NMN is subsequently converted into NAD by NMN
adenyltransferase (NMNAT). In humans, there are three
different isoforms of NMNAT with distinct tissue and
subcellular localization. OnlyNMNAT1 appears to be nu-
clear.Notably, bothNAMPTandNMNAT1performaddi-
tional functions, independent of their catalytic activity.
Extracellular NAMPT acts as a cytokine (Garten et al.
2015). NMNAT1 stimulates the catalytic activity of
PARP1, independent of NAD+ synthesis (Berger et al.
2007; Zhang et al. 2012). Moreover, Drosophila NMNAT
exhibits chaperone activity (Zhai et al. 2008). Thus, both
enzymes in theNAD+ salvage pathway performadditional
functions.
NAD+ synthesis not only is dependent on the availabil-
ity of dietary precursors but can also be determined by to-
tal caloric content. Caloric restriction leads to a switch
from glycolysis to fatty acid oxidation. One might expect
that a reduction in consumed calories leads to less oxida-
tion of nutrients in cells and tissues and, consequently, a
diminished demand for the electron acceptor function of
NAD+ (Kaelin and McKnight 2013). However, it has
been reported that caloric restriction leads to increased
levels of NAD+ (Rodgers et al. 2005; Yang et al. 2007;
Chen et al. 2008; Fulco et al. 2008). This is believed to
be a consequence of AMPK activation, which up-regulates
NAMPT, the rate-limiting enzyme of the NAD+ salvage
pathway (Yang et al. 2007; Fulco et al. 2008; Cantó et al.
2009). Conversely, mice fed on high-fat diets show de-
creased NAMPT and NAD+ levels (Yoshino et al. 2011).
Increased levels of NAD+ may activate sirtuins, leading
to the deacetylation of various cellular substrates.
Potentially relevant targets of the sirtuins include tran-
scription factors such as peroxisome proliferator-activat-
ed receptor-γ-coactivator 1α (PGC1α), FOXO1, and
FOXO3a, all of which are linked to mitochondrial and
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fatty acidmetabolism (Cantó et al. 2009, 2010).Moreover,
SIRT1 deacetylates and inhibits the glycolytic enzyme
phosphoglycerate mutase-1 (PGAM-1) (Hallows et al.
2012). SIRT3 deacetylates and activatesmitochondrial en-
zymes involved in fatty acid oxidation, including long
chain coenzyme A dehydrogenase (LCAD) (Hirschey
et al. 2010; Hebert et al. 2013). Conversely, long chain fat-
ty acids stimulate SIRT6 deacetylation in vitro (Feldman
et al. 2013). Thus, following dietary restriction, sirtuins
mediate a metabolic shift from cytosolic glycolysis to-
ward mitochondrial fatty acid oxidation through deacety-
lation of transcription factors and metabolic enzymes
(Guarente 2013). Loss of sirtuin function may also play a
role in metabolic reprogramming during oncogenesis
(Chalkiadaki and Guarente 2015).
In addition to diet,NAD+ levels canbemodulated by cir-
cadian rhythms and aging. The circadian clock influences
expression of NAMPT and, consequently, NAD+ levels
(Nakahata et al. 2009; Ramsey et al. 2009; Berger and Sas-
sone-Corsi 2015). Intriguingly, several studies reported
that NAD+ levels decline during aging (Yoshino et al.
2011,Massudi et al. 2012, Gomes et al. 2013;Mouchiroud
et al. 2013; Camacho-Pereira et al. 2016). Possible explana-
tions include accumulated DNA damage leading to in-
creased NAD+ consumption by PARP1, up-regulation of
NAD+ consumer CD38, or reduced levels of NAMPT. Al-
ternatively, decline ofmitochondrial functionmaycause a
metabolic shift toward processes that lower the NAD+/
NADH ratio. Recently, changes in NAD+/NADH ratio
have also been implicated in the transcriptional program-
ming of skeletal muscle stem cells (Ryall et al. 2015b).
Sirtuins and PARPS as NAD+ sensors
The effects of fluctuations in NAD+ levels on sirtuin and
PARP activity remain poorly understood. Generally, re-
ported changes in cellular NAD+ levels are less than two-
fold. Therefore (assuming Michaelis-Menten kinetics), to
function as NAD+ sensors, the KM of sirtuins for NAD
+
should be close to its physiological concentration. Unfor-
tunately, due to compartmentalization and its association
with proteins, it is difficult to accurately determine free
NAD+concentrations in cells and tissues.Theusualmeth-
od to measure total NAD+ levels involves acid extraction,
which will also release protein-bound NAD+. Indeed,
NAD+ levels are often reported as amounts per milligram
of protein rather than concentration. Two-photon excita-
tion microscopy in mammalian cells, which can deter-
mine the concentration of NADH but not that of NAD+,
suggested a nuclear NADH concentration of ∼110–130
nM (Zhang et al. 2002). Using a generally accepted
NAD+/NADH ratio of ∼700 under normal conditions,
this would correspond to a nuclear NAD+ concentration
of 70 µM. A recently developed biosensor revealed NAD+
concentrations in the cytosol, nucleus, and mitochondria
of 106, 109, and 230 µM, respectively (Cambronne et al.
2016). The latter value is remarkably close to the estimat-
ed mitochondrial concentration of 245 µM measured by
conventional methods (Yang et al. 2007).
The reported KM values of nuclear sirtuins are 95 µM
(SIRT1), 83 µM (SIRT2), and 26 µM (SIRT6), while report-
ed values for PARP1 are between 50 and 100 µM (Cantó
et al. 2015). Taken together, the consensus emerges that
nuclear NAD+ concentrations are within the range of
theKM values of PARP1 and SIRT1/2.Moreover, inhibito-
ry molecules such as NAMmaymodulate the apparent in
vivo KM values for NAD
+. Thus, it indeed seems reason-
able that relatively subtle changes in nuclear NAD+ levels
can modulate the activity of SIRT1, SIRT2, and PARP1,
while SIRT6 is probably unresponsive to NAD+ fluctua-
tions. The KM values for NAD
+ of PARP1, SIRT1, and
SIRT2 are very close, implying that they might compete
for the same NAD+ pool. Moreover, SIRT6 (26 µM) and
CD38 (15–25 µM) have even lower KM values for NAD
+
(Cantó et al. 2015).
PARP1 is strongly activated by DNA damage, resulting
in massive PARylation at the site of DNA damage. The
concomitant drop in NAD+ levels has been suggested to
affect sirtuin activity (Verdin 2015). Interestingly,
PARP1−/− mice show increased NAD+ levels in muscle
and brown adipose tissue as well as increased SIRT1 activ-
ity (Bai et al. 2011). The metabolisms of these mice are
substantially different from wild-type animals: They are
lighter (despite increased food intake), consume more ox-
ygen (suggesting increased energy expenditure), have a
higher mitochondrial content, and are protected against
diet-induced diabetes and obesity. Similar protective ef-
fects on diet-induced diseases have been observed in
SIRT1-overexpressing mice (Herranz and Serrano 2010)
and CD38−/− mice (Barbosa et al. 2007; Camacho-Pereira
et al. 2016). The CD38−/− mice also show increased
NAD+ levels and up-regulatedmitochondrial SIRT3 activ-
ity. Taken together, these results suggest that increased
NAD+ availability due to loss of PARP1 or CD38 function
can lead to activation of sirtuins. Conversely, increased
activity of CD38 and PARP1, causing reduced NAD+ lev-
els affecting sirtuin activity, may contribute to mitochon-
drial dysfunction during aging.
Synthesis of the universal methyl donor SAM
SAM is the universal methyl donor for cellular methyla-
tion of proteins and DNA (Figs. 2, 4A). Methionine adeno-
syltransferase (MAT) synthesizes SAM from ATP and
methionine. In this reaction, the nucleophilic sulfur
atom of methionine attacks the 5′ carbon of the ribose
moiety of ATP, resulting in the formation of SAM and tri-
phosphate, which is subsequently cleaved on the enzyme
into phosphate (Pi) and pyrophosphate (PPi). Donation of
the methyl group to an acceptor molecule (protein or
DNA) yields S-adenosylhomocysteine (SAH), which is
subsequently hydrolyzed to homocysteine and adenosine
by SAH-hydrolase (SAHH) (Locasale 2013). The methio-
nine (or methyl) cycle is completed by the donation of a
methyl group from N5-methyltetrahydrofolate (CH3-
THF), generating methionine and tetrahydrofolate
(THF). CH3-THF can be regenerated from THF in the fo-
late cycle (Tibbets and Appling 2010; Locasale 2013). In
Metabolism and gene control
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the liver and kidney, betaine-homocysteine methyltrans-
ferase (BHMT) can use betaine as a methyl donor in the
synthesis of methionine from homocysteine (Day and
Kempson 2016).
The folate cycle plays a central role in one-carbon me-
tabolism (Fig. 4B). In the folate cycle, THF serves as a scaf-
fold for the binding of a one-carbon unit that is shuffled
between the N5 and N10 atoms in the THF backbone.
One-carbon donors of the folate cycle include serine and
glycine. Many tumors up-regulate serine biosynthesis
from glycolytic intermediates. The first committed step
in this pathway is the conversion of 3-phosphoglycerate
(3-PG) into 3-phosphopyruvate (3-P-PYR) by phosphoglyc-
erate dehydrogenase (PHDG). PHDG expression is up-reg-
ulated in specific breast cancer subtypes, and genomic
regions containing the PHDG gene are amplified in mela-
noma (Locasale et al. 2011). Serine fuels the folate cycle
through the enzyme serine hydroxymethyl transferase
(SHMT), which transfers a carbon from serine to THF,
yielding glycine, N5N10-methylene-THF (CH2-THF), and
water. This reaction can occur in either the mitochondria
or the cytosol. Methylene-THF reductase converts cyto-
solic CH2-THF into CH3-THF. However, in most prolifer-
ating cultured cells, the mitochondrial pathway is used
(Ducker et al. 2016). The one-carbon unit in mitochondri-
al CH2-THF can leave the mitochondrion as formate and
enter the cytosolic folate cycle via N10-formyl-THF (10-
fTHF) synthesis (Figs. 2, 4B). In addition to serine, glycine
can also serve as a one-carbon donor. This requires the gly-
cine cleavage system, which occurs in the mitochondria.
The C2 of glycine is transferred to THF, which yields
CH2-THF. The C1 of glycine is released as CO2 and the
amino group as NH3.
Although most organisms can synthesize methionine,
this does not suffice in humans, making it an essential
amino acid that needs to be provided in the diet. Impor-
tantly, the one-carbon unit attached to THF not only is
used for the synthesis of methionine but is also essential
for de novo synthesis of purines and dTMP. In the case
of purines, the one-carbon unit is donated from 10-fTHF.
The one-carbon unit for the synthesis of dTMP originates
from CH2-THF. THF itself is made in two steps from
dietary folate (vitamin B9) by dihydrofolate reductase
(DHFR). Reflecting the importance of the folate cycle for
proliferation, DHFR is the target of the anti-tumor agent
methotrexate (MTX). In summary, the folate cycle is fun-
damentally important for cellular methylation reactions
through methionine synthesis and for cell proliferation
by regulating the synthesis of purines and dTMP.
Chromatin methylation is modulated by nutrient
availability
Although requirements differ between different cell types
and organisms, multiple studies demonstrated effects of
nutrient restriction on histone methylation. As discussed
above, mESCs (but not hESCs) are dependent on the activ-
ity of mitochondrial threonine dehydrogenase that catab-
olizes threonine into glycine and acetyl-CoA (Wang et al.
2009). This metabolic route has consequences beyond
acetylation because the glycine that is produced enters
the glycine cleavage pathway. Tracing studies revealed
that the one-carbon unit from threonine appears in CH3-
THF and SAM (Shyh-Chang et al. 2013). Indeed, threonine
restriction results in a drop in the SAM/SAH ratio, ac-
companied by a decrease in H3K4me2/3 and increased
mESC differentiation. Threonine restriction does not af-
fect other histone methylation marks, such as H3K9me3
and H3K27me3, suggesting differential sensitivity of
KMTs for SAM levels. What remains unclear is whether
the global reduction of H3K4me2/3 directly causes a
gene expression program that promotes stem cell differen-
tiation. In hESCs or human induced PSCs (iPSCs), methi-
onine restriction results in reduced H3K4me3 levels,
while there is no effect on H3K9me3, H3K27me3, and
H3K36me3 levels (Shiraki et al. 2014). Thus, regardless
of the nutrient source, maintenance of global H3K4me3
levels in stem cells requires high SAM levels, while the
threshold for other histone methylation marks is lower.
These effects are not limited to stem cells. Methionine
restriction in various human cell lines also results in de-
creased levels of H3K4me3 (Mentch et al. 2015). This
was an unexpected observation because, in principle, me-
thionine can be recycled from SAH through donation of a
methyl group from CH3-THF. However, in these cancer
cells, the folate andmethionine cycles are uncoupled, pre-
venting the conversion of SAH into SAM. This suggests
that homocysteine is not converted into methionine but
is used in other pathways, such as synthesis of cystathio-
nine. Consequently, serine, which fuels the folate cycle
with one-carbon units in cancer cells (Labuschagne et al.
2014), cannot compensate for methionine deprivation.
This blockage can be circumvented by supplementation
of the culture medium with homocysteine and vitamin
B12 (Maddocks et al. 2016). Under these conditions, it
was found that serine contributes to the production of
SAM by providing one-carbon units for the synthesis of
methionine from homocysteine and supporting de novo
ATP synthesis (Maddocks et al. 2016). Serine starvation
led to a drop in both ATP and AMP (hence, AMPK was
not activated), thus distinguishing between de novo ATP
synthesis and ATP turnover. In summary, serine metabo-
lism supports methylation in cancer cells by two distinct
pathways: first, through de novo ATP synthesis, which is
required for the conversion of methionine into SAM; and
second, through fueling the folate cycle with one-carbon
units, which can then be used for synthesis of methionine
from SAH via homocysteine. Note that if sufficient me-
thionine is available, the latter does not occur.
The effects of SAM reduction on global H3K4 methyla-
tion levels are not restricted to vertebrates. In Saccharo-
myces cerevisiae, folate and methionine deficiency leads
to reduced H3K4me2 and H3K4me3 levels (Sadhu et al.
2013). Knockout of the enzymes sam1 or sam2, which
are the orthologs of MAT, also diminishes H3K4me3 lev-
els (Li et al. 2015). Caenorhabditis elegans contains four
MAT homologs, known as sam1–4. Knockdown of sam1
reduces H3K4me3 (Ding et al. 2015) However, simultane-
ous knockdown of sam3 and sam4 leads to a reduction in
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H3K9me3,H3K27me3, andH3K36me3but does not affect
H3K4me3 (Towbin et al. 2012). The underlyingmolecular
mechanism isunclear butmight reflect differences in local
production of SAM. In this regard, the recruitment of
MATIIα, one of themammalianMAT isoforms, to specific
chromatin sites by transcription factorMafK is suggestive
(Katoh et al. 2011; Kera et al. 2013). As part of the S. cere-
visiae SESAME (serine-responsive SAM-containing meta-
bolic enzyme) complex, sam1 and sam2 are recruited to
specific chromatin loci and interact with the H3K4 HMT
Set1 (Li et al. 2015). Thus, local SAM production might
stimulate specific HMTs.
Cofactors, cosubstrates, and inhibitors of chromatin
demethylation
There are two major classes of KDMs, each of which de-
pends on different cofactors (Fig. 4A; Kooistra and Helin
2012). Demethylation by LSD1 or LSD2 requires FAD,
which is synthesized de novo from vitamin B2. Like
NAD+, FAD acts as an electron acceptor and is used in a
wide variety of cellular redox reactions. During the deme-
thylation reaction, LSD1/2 catalyzes the oxidation of
the methylamine group, coupled to FAD reduction to
FADH2 (Walport et al. 2012).This step results in the forma-
tion of an imine bond (a carbon–nitrogen double bond,
with the nitrogen attached to a hydrogen atom or an alkyl
group). Next, FADH2 is oxidized by molecular oxygen, re-
sulting in regeneration of FAD and formation of hydrogen
peroxide. In the second step of the reaction, the imine bond
is resolved through reaction with water, resulting in the
formation of an N–H bond and formaldehyde. Note that
the formationof an imine (double) bond as an intermediate
step in the reaction is the reason that LSD-class demethy-
lases cannot use trimethylated lysines as a substrate.
JMJC KDMs and TET DNA demethylases are αKG-de-
pendent dioxygenases that use αKG (also known as 2-
oxo-glutarate) as a cosubstrate (Figs. 2, 4A). The demethy-
lation reaction requires Fe(II) and consumes αKG and O2,
producing succinate,CO2, and formaldehyde.αKGisan in-
termediate of the TCA cycle and is synthesized in the mi-
tochondria from isocitrate by isocitrate dehydrogenase 2
(IDH2) and IDH3. A third family member, IDH1, is local-
ized in the cytosol and peroxisomes. While IDH1 and
IDH2 use NAD phosphate (NADP+) as a cofactor, IDH3
uses NAD+. In the TCA cycle, αKG is oxidized into suc-
cinyl-CoA. In addition to protein and DNA demethyla-
tion, αKG-dependent dioxygenases include enzymes
involved inoxygensensing, fattyacidmetabolism,andcol-
lagen biosynthesis. Importantly, several metabolites that
are structurally related to αKG are inhibitors of αKG-de-
pendent dioxygenases. These include succinate, fumarate,
and 2-hydroxyglutarate (2HG). Succinate and fumarate are
intermediates of the TCA cycle, but succinate is also pro-
duced as a product of αKG-dependent dioxygenases.
Finally, αKG also serves important functions in amino
acid metabolism. Together with glutamate, αKG forms
an amino and α-keto acid pair in transamination reactions
by aminotransferases. In amino acid catabolism, αKG acts
as an amino group acceptor, yielding glutamate. Vice ver-
sa, in amino acid biosynthesis, glutamate acts as an amino
group donor, yielding αKG. If the nitrogen is not required
for biosynthesis, glutamate can also be deaminated by glu-
tamate dehydrogenase (GDH), which releases the amino
group as ammonia, yielding αKG (DeBerardinis 2016). In
proliferating cells, the activity of aminotransferases is
up-regulated, coupling amino acid synthesis to αKG gen-
eration (Coloff et al. 2016). Conversely, quiescent cells
display enhanced GDH levels and reduced levels of
aminotransferases.
αKGmodulates stem cell pluripotency and differentiation
mESCs depend on glucose and glutamine catabolism to
maintain high levels of αKG,which promotes self-renewal
over differentiation (Carey et al. 2015). Glutamine depri-
vation results in a drop in the αKG/succinate ratio, ac-
companied by increased global methylation of some
histone residues, including H3K27me3. Likewise, DNA
demethylation by the TET proteins is also affected by
glutamine starvation, leading to hypermethylation. How-
ever, H3K4me3 and some other methylated histone resi-
dues remained unchanged. Thus, there appears to be a
hierarchy in the sensitivity for changes in the αKG/succi-
nate ratio among different methylated histone residues.
The molecular basis for this selectivity remains unclear.
Another important question is how a shift in chromatin
methylation may affect the gene expression programs for
either self-renewal or differentiation.
Recently, it was suggested that transcriptional regula-
tion of αKG synthesis is an integral part of pluripotency
control (Hwang et al. 2016).One of the enzymes that deter-
mine αKG levels in mESCs is phosphoserine aminotrans-
ferase 1 (Psat1), which is part of the serine biosynthetic
pathway.Hwang et al. (2016) showed thatPsat1expression
is controlled by the stem cell core transcription factors
Oct4, Sox2, and Nanog. Psat1 is highly expressed in
mESCs and is down-regulated upon differentiation. Psat1
catalyzes the conversion of 3-P-PYR into 3-phosphoserine
(3-P-Ser) using glutamate as amino donor, yielding αKG
(Fig. 2).KnockdownofPsat1 reduces theαKG/succinate ra-
tio and leads toDNAhypermethylation and increased lev-
els of H3K9me3 and H3K36me3, whereas no effect was
observed on H3K27me3. Reduced αKG levels suppress
mESC self-renewal and accelerate differentiation. These
observations suggest that transcriptional control of meta-
bolic enzymePsat1 affects αKG levels, which in turnmod-
ulate the mESC pluripotency program.
Complicatingmatters, the precise stage of PSCs and the
cellular context turns out to be amajor factor in determin-
ing the effect of αKG on self-renewal. In primed human
PSCs or mouse epiblast stem cells (EpiSCs), which are
more mature than mESCs, αKG promotes differentiation
instead of self-renewal (TeSlaa et al. 2016). As αKG stimu-
lates bulk histone and DNA demethylation in both Epi-
ESCs and ESCs, the effects of αKG on stem cell self-
renewal or differentiation seem to depend on cellular
maturity.
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Oncometabolites that counteract αKG
Cancer-associated mutations in several genes encoding
enzymes involved in the TCA cycle cause the accumula-
tion of metabolites that are competitive inhibitors of
αKG-dependent dioxygenase reactions (Fig. 4A). Loss-of-
function mutations in mitochondrial enzymes succinate
dehydrogenase (SDH) and fumarate hydratase (FH) have
been identified in a subset of relatively rare human can-
cers. As a result of these mutations, succinate and fuma-
rate accumulate, leading to inhibition of JMJC-class
KDMs and TET DNA demethylases (Xiao et al. 2012; Kil-
lian et al. 2013; Letouzé et al. 2013). Loss of FH and ac-
cumulation of fumarate has been connected to the
epithelial-to-mesenchymal transition (EMT). Inhibition
of TET-mediated demethylation by fumarate affects ex-
pression of the anti-metastatic microRNA cluster mir-
200ba429, resulting in the expression of EMT-related
transcription factors (Sciacovelli et al. 2016). Gain-of-
function mutations in IDH1 and IDH2, which occur in a
subset of gliomas and acute myeloid leukemias (AMLs),
generate neomorphic enzymes. Instead of αKG, cancer-as-
sociated IDH1/2 mutants produce the R-enantiomer of
2HG (R-2HG) (Dang et al. 2009; Gross et al. 2010; Ward
et al. 2010). Strikingly, cancer cells harboring neomorphic
IDH1/2 mutants have R-2HG levels that are >10-fold to
300-fold higher than normal (Losman and Kaelin 2013).
R-2HG is a competitive inhibitor of JMJC-class KDMs
and TET DNA demethylases, resulting in DNA and his-
tone hypermethylation (Figueroa et al. 2010; Chowdhury
et al. 2011; Xu et al. 2011; Koivunen et al. 2012; Lu et al.
2012; Turcan et al. 2012). Indeed, gliomas and AML cells
harboring IDH1 mutations have a so-called CpG island
methylator phenotype: aberrant methylation of CpG is-
lands on a subset of genes (Toyota and Issa 1999). Affected
genes include the crucial tumor suppressor p16INK4a, pro-
viding an attractive molecular explanation for how R-
2HG may drive oncogenesis. However, direct proof for
this notion remains elusive.
Although there is compelling evidence that R-2HG is a
dominant oncogenic effector, it is less clearwhich cellular
process is the crucial target for cellular transformation
(Losman et al. 2013). Experiments using an inhibitor
that is selective for themost common IDH1mutant in gli-
omas suggested that reversal of oncogenic features is inde-
pendent of chromatin methylation effects (Rohle et al.
2013). Moreover, the S-enantiomer of 2HG (S-2HG) is a
more potent inhibitor of TET2 DNA demethylase than
R-2HG but does not induce cellular transformation (Los-
man et al. 2013). Thus, it remains unresolved which of
the >50 αKG-dependent dioxygenases are the relevant tar-
gets in oncogenesis. One possible candidate is the prolyl
hydroxylase EgIN, which is inhibited by S-2HG but stim-
ulated by R-2HG (Koivunen et al. 2012; Losman et al.
2013). EgIN controls the levels of the HIF transcription
factors, which play important roles in cancer biology (Maj-
mundar et al. 2010; Keith et al. 2011).
In summary, cancer-associated mutations in SDHs,
FHs, and IDHs result in an increase of succinate, fuma-
rate, or R-2HG, which inhibit JMJC domain-containing
KDMs and TET DNA demethylases. However, whether
the associated changes in chromatin are drivers of onco-
genic transformation remains to be determined.
Metabolic enzymes that do double duty as regulators
of chromatin and transcription
Thus far, we have discussed the rapidly expanding study of
the influence of metabolites on gene expression. In addi-
tion, some metabolic enzymes turned out to play surpris-
ingly direct roles in the regulation of chromatin and
transcription. Below, we discuss examples of metabolic
enzymes that do double duty as regulators of transcrip-
tion. We note, however, that there are other routes
through which metabolic enzymes may modulate gene
expression. For example, screens for RNA-binding pro-
teins turned up a large number ofmetabolic enzymes, sug-
gesting that they may be involved in post-transcriptional
control (for review, see Castello et al. 2015). Aminoacyl-
tRNA synthetases (aaRSs) catalyze the coupling of specif-
ic amino acids to tRNAs for protein synthesis. Indepen-
dent of their enzymatic function in translation, aaRSs
engage in a plethora of additional cellular functions
(Guo and Schimmel 2013). Here, we concentrate on chro-
matin and transcription control by metabolic enzymes.
We discuss selected examples that highlight the diverse
ways in which metabolic enzymes can modulate gene ex-
pression. These include functioning as sequence-specific
transcription factors, as transcriptional coregulators, or
by localized cofactor production. Notably, control of
gene expression often does not involve the enzyme’s cat-
alytic activity. Finally, cytoplasmic–nuclear partitioning
is used repeatedly as a regulatory mechanism to link met-
abolic state to transcriptional outcomes (Fig. 1).
Chromatin modulation by PK and SESAME
PK catalyzes the final step of glycolysis, which is the con-
version of PEP and ADP into pyruvate and ATP. Like
many other glycolytic enzymes, PK is frequently up-regu-
lated in tumors. The mammalian enzyme comprises four
isoforms encoded by two different genes (Israelsen and
Vander Heiden 2015). PKM1 and PKM2 are encoded by
the PKM gene and differ due to alternative splicing.
PKM2 is the predominant isoform in cancer cells but is
also expressed in normal proliferating cells (Altenberg
and Greulich 2004; Mazurek et al. 2005). Strikingly, re-
placement of PKM2 by PKM1 leads to reversal of theWar-
burg effect, as judged by increased oxygen consumption
and diminished lactate production (Christofk et al.
2008). Disappointingly, instead of the expected inhibition,
deletion of the exon required for the PKM2 isoform accel-
erates mammary tumor formation in a Brca1-loss mouse
model (Israelsen et al. 2013). Thus, the precise role of
PKM2 in tumorigenesis remains confusing. PK shows
the highest activity as a tetramer. PKM1 forms a constitu-
tive tetramer, while the oligomeric state and activity of
PKM2 is regulated by a multitude of different mecha-
nisms, including PTMs and allosteric effectors. For
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example, PKM2 is allosterically activated by serine (Cha-
neton et al. 2012; Ye et al. 2012).When serine is abundant,
PKM2 is fully active, resulting inmaximal glycolytic flux.
Serine deprivation results in reduced PKM2 activity, en-
abling the shuttling of glucose-derived carbon into the
serine biosynthesis pathway. Another allosteric activator
is succinyl-aminoimidazole-carboxamide-ribose-5-phos-
phate (SAICAR), which is an intermediate in the purine
biosynthetic pathway. Glucose restriction in cancer cells
results in accumulation of SAICAR, which activates
PKM2, promoting lactate production and cell survival
(Keller et al. 2012). Thus, PKM2 controls glycolysis and
the synthesis of biomolecular building blocks in response
to metabolic cues.
Apart from its canonical function as a glycolytic en-
zyme, PKM2 has also been implicated in chromatin regu-
lation. PKM2 translocates to the nucleus in response to
EGF signaling, interleukin-3, hypoxia, or SAICAR (Ho-
shino et al. 2007; Keller et al. 2012; Luo et al. 2011;
Yang et al. 2011). Remarkably, in the nucleus, PKM2
acts as a protein kinase that uses PEP as a phosphate donor
instead of ATP (Gao et al. 2012; Yang et al. 2012). One of
the nuclear phosphorylation targets of PKM2 is H3T11
(Yang et al. 2012). H3T11 phosphorylation by PKM2 in
promoter regions of target genes, including MYC and
CCND1 (cyclin D1), results in HDAC3 dissociation and
subsequentH3K9ac.However, theproteinkinase function
of PKM2 is controversial. It has been suggested that the ob-
served activity is due to ATP containing PEP batches or
ATP regeneration by PKM2, which is subsequently used
byother protein kinases (Hosios et al. 2015).Nevertheless,
a recent report suggests that H3T11 phosphorylation by
PKM is conserved from yeast to humans (Li et al. 2015).
S. cerevisiae has two PK homologs: Pyk1 and Pyk2.
H3T11 phosphorylation (H3pT11) is reduced in a temper-
ature-sensitive strain of Pyk1 when grown at the non-
permissive temperature, while no effect on H3T11
phosphorylation was observed in a Pyk2 deletion strain
(Li et al. 2015). Thus, mammalian PKM2 seemsmore sim-
ilar to Pyk1 than to Pyk2. Surprisingly, Pyk1 is found in a
complex with enzymes involved in serine, SAM, and ace-
tyl-CoA synthesis, which was duly named SESAME (Li
et al. 2015). SESAMEphosphorylatesH3T11 in a serine-re-
sponsive way, indicating that the allosteric activation by
serine is evolutionary conserved. The presence of both ser-
ine and SAMbiosynthetic enzymes in SESAME suggests a
functional link between both pathways (Fig. 5A). As dis-
cussed above, serine biosynthesis and SAM biosynthesis
are linkedvia the folate cycle, forwhich serine acts as acar-
bon donor. Deletion of either serine or SAM biosynthetic
enzymes in SESAME reduces global H3K4me3 levels.
Concurrently, H3pT11 phosphorylation is reduced, sug-
gesting a dependence on H3K4me3. Indeed, deletion of
various subunits of the Set1 complex (also known as
COMPASS [complex of proteins associated with Set1]),
which is responsible forH3K4methylation in S. cerevisiae
(Shilatifard 2012), reduces not only H3K4me1/2/3 but
also H3pT11. These findings suggest that Set1-dependent
H3K4 methylation facilitates H3T11 phosphorylation by
SESAME. Conversely, biosynthesis of serine or SAM by
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Figure 5. Metabolic enzymes as transcription factors. (A) The
chromatin-associated SESAME complex harbors PK, a subset of
serine metabolic enzymes, and SAM synthetases. The Set1
H3K4 methyltransferase complex promotes the recruitment of
SESAME and H3T11 phosphorylation. SESAME provides a con-
nection between H3K4me3, H3pT11, glycolysis, and serine me-
tabolism. Forming a feedback loop, SESAME autoregulates PYK1
gene expression. (Met) Methionine; (pyr) pyruvate; (3-P-Ser) 3-
phospho-serine. (B) Chromatin and transcription control by nu-
cleotide biosynthetic enzymes. In the cytoplasm, inosine mono-
phosphate (IMP) dehydrogenase (IMPDH) and guanosine 5′-
monophosphate (GMP) synthase (GMPS) mediate the synthesis
of GMP. In the nucleus, GMPS binds and activates the deubiqui-
tylating enzyme ubiquitin-specific protease 7 (USP7). GMPS-
USP7 can function as a transcriptional corepressor when it is re-
cruited to specific regulatory elements (REs) by gene-selective
transcription factors (TFs). Here, GMPS-USP7 can promote
gene repression at least in part by removal of the active H2B ubiq-
uitylation (H2Bub) mark (ub; green hexagons). GMPS-USP7 is re-
cruited to Polycomb response elements and promotes silencing
by the Polycomb system. USP7 can deubiquitylate selective Pol-
ycomb group (PcG) proteins, thereby promoting H2Aub. In addi-
tion to acting as a transcriptional corepressor, GMPS-USP7 can
also modulate gene expression programs through deubiquityla-
tion and stabilization of selective transcription factors, including
the tumor suppressor p53 and the effector of hedgehog signaling,
cubitus interruptis. Although the majority of GMPS is cytoplas-
mic, it continuously shuttles in and out of the nucleus. The nu-
clear accumulation of GMPS and hence its impact on gene
expression are regulated by cellular state. IMPDH is the enzyme
directly upstream of GMPS. In addition to its biosynthetic func-
tion, IMPDH is also a sequence-specific DNA-binding transcrip-
tional repressor. IMPDH binds single-stranded CT-rich
regulatory DNA elements (C/T). Cytoplasmic–nuclear partition-
ing is used to regulate IMPDH nuclear activity. Normally, most
IMPDH is cytoplasmic, but it accumulates in the nucleus in re-
sponse to oxidative or replicative stress.
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SESAME may fuel H3K4me3 methylation. However,
some key enzymes in the SAM and serine synthesis
pathways are lacking in SESAME. Thus, for localized pro-
duction on chromatin, these enzymes will need to be re-
cruited as well. Set1 facilitates the binding of SESAME to
target genes in response to changes in serine metabolism.
Interestingly, these target genes includePYK1,which is re-
pressed by SESAME. These results suggest that SESAME
may convert changes in intermediarymetabolism to chro-
matin structure, constituting a negative feedback loop to
PYK1 expression.
Transcriptional repression by fructose-1,6-bisphosphatase
(FBP1)
FBP1 is the rate-limiting enzyme in the gluconeogenesis
pathway, which generates glucose from noncarbohydrate
sources.Metabolic profiling of clear cell renal cell carcino-
mas (ccRCCs) revealed that gluconeogenesis was uni-
formly suppressed and that FBP1 is depleted (Li et al.
2014). FBP1 down-regulation is crucial for ccRCC cell pro-
liferation, in particular in cells where HIF1α is stabilized.
The vast majority of ccRCCs contains inactivating muta-
tions in the von Hippel-Lindau (VHL) E3 ubiquitin ligase,
which leads to HIF1α stabilization even under normoxia.
The transcriptional activity of HIF1α in turn drives angio-
genesis and metabolic reprogramming, benefitting tumor
growth. Li et al. (2014) found that FBP1 bound to the HIF
inhibitory domain and suppressed HIF1α transcriptional
activity in ccRCC cells. FBP1 and HIF1α colocalize on
hypoxia response DNA elements, suggesting that FBP1
acts as a transcriptional corepressor. Pertinently, tran-
scriptional repression of HIF1α target genes was indepen-
dent of FBP1 catalytic activity. This fascinating study
suggests that FBP1 has a dual tumor-suppressive function
in renal cancer. First, its metabolic activity in the cyto-
plasm may antagonize glycolytic flux and thereby the
Warburg effect. Second, in the nucleus, it can function
as aHIF1 transcriptional corepressor. Thus, FBP1 provides
a direct coupling between metabolic and transcriptional
adaptation.
The diverse functions GAPDH
GAPDH is probably best known among molecular biolo-
gists for its humble role as a loading or normalization con-
trol. However,GAPDH is an important glycolytic enzyme
that catalyzes the conversion of glyceraldehyde-3-phos-
phate into 1,3-bisphosphoglycerate. The majority of
GAPDH normally exists as a tetramer in the cytoplasm.
Following distinct cellular stressors, however, GAPDH
relocalizes to various organelles, including the nucleus,
mitochondria, and subcellular structures such asmicrotu-
bules. At these novel locations, GAPDH has been impli-
cated in a stunning variety of activities (for review, see
Tristan et al. 2011). Just in the nucleus, GAPDH functions
inDNA repair, cell cycle-dependent transcription control,
RNA export, telomere maintenance, induction of autoph-
agy, and cell death. GAPDHwas identified as an essential
component of the transcriptional coactivator OCA-S,
which drives the expression of the histone H2B gene at S
phase (Zheng et al. 2003; Dai et al. 2008). The sequence-
specific transcription factor OCT1 recruits GAPDH,
which contains intrinsic transcriptional activation poten-
tial, to theH2Bpromoter.WithinOCA-S,GAPDHappears
tobemonomeric, precluding its enzymatic activity,which
depends on tetramerization. NAD+ activates, but NADH
inhibits, binding to OCT1 and transcription activation.
These findings suggest that GAPDH can confer redox con-
trol on transcription of selective genes. It will be interest-
ing to see whether these initial observations can be
expanded and whether the gene regulatory network of
GAPDH can be determined.
Nuclear GAPDH plays a pivotal role in controlling the
balance between apoptosis and autophagy. Diverse cyto-
toxic stresses induce S-nitrosylation of GAPDH (SNO-
GAPDH),which blocks its catalytic activity and promotes
binding to the E3 ubiquitin ligase SIAH1 and nuclear
translocation (Sen et al. 2008). Nuclear SNO-GAPDHme-
diates apoptosis through stimulation of p300/CBP, which
acetylates and activates p53 (Sen et al. 2008). Moreover,
SNO-GAPDH can bind and transnitrosylate SIRT1 and
HDAC1, leading to their inhibition (Kornberg et al.
2010). Under different conditions, however, GAPDH can
function as an activator of SIRT1 (Chang 2015). Following
glucose deprivation, but not amino acid starvation,
GAPDH is phosphorylated by AMPK. This leads to
GAPDH accumulation in the nucleus, where it activates
SIRT1 by displacement of the repressor DBC1. The active
SIRT1 deacetylase can now stimulate an anti-apoptotic
cellular autophagy program (Chang et al 2015). In sum-
mary, depending on the cellular stress, GAPDH can be
either S-nitrosylated or phosphorylated, which will pro-
mote nuclear protein acetylation or deacetylation, respec-
tively. This in turn can trigger either apoptosis or cell
survival via authophagy. Thus, GAPDH integrates and re-
lays different cellular signals and, through its nuclear non-
enzymatic activity, mediates opposing outcomes.
Chromatin and transcription control by nucleotide
biosynthetic enzymes
Cell growth and proliferation depend on de novo nucleo-
tide biosynthesis. To this end, cancer cells and normal
rapidly dividing cells redirect glucose and glutamine to-
ward nucleotide anabolic pathways and induce the expres-
sion of key nucleotide biosynthetic enzymes (Tong et al.
2009). Conversely, repression of nucleotide metabolism
plays a key role in oncogene-induced cellular senescence
(Aird et al. 2013). Thus, cells need to coordinate growth,
differentiation, and tumor suppression with nucleotide
biosynthesis. It is well established that transcription fac-
tors such as Myc and E2F control the transcription of
genes encoding key nucleotide biosynthetic enzymes
(Dang and Lewis 1997; Tong et al. 2009). However, the
molecular nature of a potential feedback loop remained
unclear. Recent research revealed a direct role for selec-
tive nucleotide biosynthetic enzymes in coupling cellular
van der Knaap and Verrijzer
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state to gene expression programs during development
and in tumor suppression.
Guanosine 5′-monophosphate (GMP) synthase (GMPS)
is a biosynthetic enzyme that mediates the final step of
the de novo synthesis of guanine nucleotides, converting
xanthosine 5′-monophosphate (XMP) intoGMP. In this re-
action, glutamine acts as anamido-Ndonorand is convert-
ed into glutamate. Studies inDrosophila and human cells
found that GMPS associates with the nuclear ubiquitin-
specific protease 7 (USP7) (van der Knaap et al. 2005,
2010; Sarkari et al. 2009; Reddy et al. 2014; Zhou et al.
2015). GMPS activates USP7 through an allostericmecha-
nism,which is independent of its GMP synthesis function
(vanderKnaap et al. 2005, 2010; Faesen et al. 2011).GMPS-
USP7modulates gene expression by targeting either chro-
matin or transcription factors (Fig. 5B). Biochemical and
genetic evidence established thatGMPS is required for his-
tone H2B deubiquitylation by USP7 in Drosophila and
mammalian cells (van der Knaap et al. 2005, 2010; Sarkari
et al. 2009; Frappier and Verrijzer 2011). In Drosophila,
GMPS-USP7 functions as a transcriptional corepressor
that is recruited to target genes by the ecdysone nuclear re-
ceptor (van der Knaap et al. 2010).
GMPS and USP7 are genetic enhancers of Polycomb
function in Drosophila. GMPS-USP7 is recruited to Poly-
comb response DNA elements and promotes silencing of
homeotic genes by the Polycomb system (van der Knaap
et al. 2005). Removal of the active H2B monoubiquityla-
tion (H2Bub1) mark by GMPS–USP7 provides a straight-
forward explanation for its cooperation with Polycomb
group (PcG) silencing. However, it is not clear whether
this is the actualmechanism.Whereas USP7 has been im-
plicated in Polycomb repression in human cells, the po-
tential role of GMPS has not been examined yet.
Research in mammalian cells revealed that USP7 associ-
ates with selective PcG proteins, thereby modulating
their level and activity, including H2Aub (Maertens
et al. 2010; Frappier and Verrijzer 2011; Lecona et al.
2015). Thus, USP7 can create a repressive chromatin envi-
ronment by deubiquitylation of H2Bub (a mark of active
chromatin) and stimulates H2Aub (a mark of repressed
chromatin).
In addition to acting as a transcriptional corepressor,
GMPS-USP7 can also modulate gene expression pro-
grams through deubiquitylation of selective transcription
factors. Elegant developmental genetic experiments in
Drosophila revealed that both GMPS and USP7 are re-
quired for hedgehog signaling (Zhou et al. 2015). The
hedgehog signaling pathway plays crucial roles in normal
development and tissue homeostasis in organisms rang-
ing from invertebrates to mammals (Briscoe and Thérond
2013). The ultimate effector of hedgehog signaling is
the sequence-specific transcription factor cubitus inter-
ruptis (Ci; named Gli in mammals). Ci is controlled by
several ubiquitin E3 ligases followed by partial or
complete proteasomal degradation. Depending on the
strength of the hedgehog signal, Ci can either be degraded,
form a truncated transcriptional repressor, or act as a
full-length activator. Zhou et al. (2015) showed that
GMPS-USP7 is a positive mediator of hedgehog signaling
through deubiquitylation and stabilization of the active
form of Ci.
Finally, GMPS-USP7 is a regulator of the p53 tumor
suppressor pathway (Reddy et al. 2014). The sequence-spe-
cific transcription factor p53 is a crucial mediator of tu-
mor suppression but also regulates metabolism and
stem cell biology (Bieging et al. 2014). p53 levels are tight-
ly controlled and involve multiple pathways, including
ubiquitylation. Normally, p53 protein levels are kept
low due to continuous ubiquitylation by the E3 ubiquitin
ligase MDM2 followed by proteasomal degradation.
(Hock and Vousden 2010). USP7 plays a dual role in p53
regulation and may deubiquitylate either p53 or its nega-
tive regulator, MDM2 (Cummins et al. 2004; Li et al.
2002, 2004). Interestingly, GMPS acts as a relay linking
cellular state to p53 stabilization by USP7 (Reddy et al.
2014). Most GMPS is normally sequestered in the cyto-
plasm, whereas, in the nucleus, MDM2 binds and ubiqui-
tylates p53, marking it for proteasomal degradation. USP7
counteracts autoubiquitylation of MDM2, thereby pro-
moting p53 degradation. Genomic stress or nucleotide
deprivation signals the nuclear accumulation of GMPS.
Here, it stabilizes p53 by driving its transfer from
MDM2 to a GMPS-USP7 deubiquitylation complex. In-
triguingly, cytoplasmic retention of GMPS involves
TRIM21, a ubiquitin ligase involved in immune regula-
tion (Reddy et al. 2014).
In conclusion, GMPS can either enable or restrict
cell proliferation. The biosynthetic function of GMPS
provides the nucleotides needed for cellular growth and
DNA replication. In the nucleus, GMPS can stabilize
p53 through redirection and activation of USP7. These
opposing activities of GMPS indicate a regulatory loop
to restrict aberrant cell proliferation. Finally, the gene
regulatory functions of GMPS in Polycomb silencing
and ecdysone and hedgehog signaling suggest that it cou-
ples cell differentiation, growth, and proliferation during
development.
Inosine monophosphate (IMP) dehydrogenase (IMPDH)
is the enzyme directly upstreamof GMPS in theGMPbio-
synthesis pathway (Hedstrom 2009). IMPDH catalyzes
the oxidation of IMP to theGMPS substrate XMP, concur-
rently reducingNAD+ toNADH. In addition to its biosyn-
thetic function, there is evidence that IMPDH is involved
in gene expression control (Fig. 5B). IMPDH can bind
RNA and polysomes and has been implicated in selective
control of translation (Mortimer et al. 2008). Studies in
Drosophila showed that IMPDH is also a sequence-specif-
ic DNA-binding transcriptional repressor that binds
unwound CT-rich regulatory DNA elements (Fig. 5B;
Kozhevnikova et al. 2012). Most IMPDH is normally
cytoplasmatic but accumulates in the nucleus during
the G2 phase of the cell cycle or in response to oxidative
or replicative stress. Interestingly, IMPDH binds and re-
presses the histone genes and E2f, the master controller
of the G1/S transition. These observations suggest that,
as biosynthetic enzymes, GMPS and IMPDH fuel cell
growth and proliferation but, as regulators of transcrip-
tion, restrain these processes. Such a coupling of activities
may safeguard against aberrant cell proliferation.
Metabolism and gene control
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Metabolism and epigenetic inheritance
Because chromatin-modifying enzymes depend on key
metabolites, nutritional state can influence the structure
of chromatin and gene expression. A topic of considerable
current interest is towhat extent nutritional history or en-
vironmental stress may modulate epigenetic inheritance.
Much has been said about themeaning of the term “epige-
netics” (Bird 2007; Ptashne 2007; Allis and Jenuwein
2016). One popular definition of epigenetics refers to ef-
fects on gene expression that are maintained through
cell divisions in the absence of the initiating signal (and
that do not involve mutations in the DNA sequence). A
classic example of such a process is the establishment of
homeotic gene expression in the fruit fly. During develop-
ment ofDrosophila, the expression domains of the home-
otic genes are established early in development by the gap
and pair rule sequence-specific transcription factors.
However, these transcription factors are expressed only
transiently and disappear later during development. The
faithful inheritance of the previously established expres-
sion pattern of the homeotic genes now requires the activ-
ities of the PcG and trithorax group (trxG) proteins. PcG
proteins maintain repression of homeotic genes outside
their normal expression domains, whereas trxG proteins
are needed to sustain transcription. Once established, si-
lencing or activity is mitotically stable and maintained
over many cell divisions. Pertinently, PcG and trxG pro-
teins regulate transcription through modulation of chro-
matin structure. PcG silencing depends on methylation
of histone H3K27 by PRC2. The H3K27R substitution
mutation, which can no longer bemethylated, reproduces
the PcG mutant phenotype in Drosophila (Pengelly et al.
2013). Thus, specific chromatin modifications can be cru-
cial for the cellularmemory of transcriptional state during
metazoan development. A broader definition of epigenetic
events is “the structural adaptation of chromosomal re-
gions so as to register, signal, or perpetuate altered activity
states” (Bird 2007). Often, however, epigenetics is used to
cover virtually all aspects of chromatin structure, histone
PTMs, or DNA methylation. On the opposite end of the
spectrum, epigenetics is used to describe transgenera-
tional inheritance of a phenotype induced through inter-
action with the environment, such as the nutritional
state of a parent (again, without alterations in the genome
sequence). Problems arise when these meanings become
intermingled, and chromatin modifications are implicitly
assumed to mediate transgenerational inheritance.
As discussed above, nutritional state canmodulate gene
expression patterns involving changes in chromatin struc-
ture (including H3K27 methylation). Thus, these effects
can be referred to as epigenetic. In our opinion, however,
there is no compelling evidence for transgenerational
inheritance of broad patterns of gene expression (e.g., con-
ferring a metabolic ground state) in mammals. Transge-
nerational inheritance of acquired states is especially
well established in plants and has also been observed in
animals such as C. elegans. In these organisms, RNA is
likely to play a major role in the stable inheritance of
gene expression state. For two outstanding reviews on
transgenerational epigenetics, seeDaxinger andWhitelaw
(2012) andHeard andMartienssen (2014). There are exam-
ples of stable epialleles in mammals, such as in the
Agoutivy mice, but these tend to be special cases often in-
volving transposable DNA elements. Similarly, parental
imprinting affects only a small subset of genes. Conclu-
sive evidence for chromatin-based inheritance in mam-
mals is lacking. Frequently mentioned epidemiological
studies—e.g., those on the effects of the Dutch hunger
winter of 1945 on progeny (Schulz 2010)—remain phe-
nomenology and do not provide amechanistic basis. In ad-
dition, we are concerned whether it is possible to correct
appropriately for confounding factors such as social influ-
ences. Finally, it is important to distinguish developmen-
tal defects from transgenerational epigenetic inheritance.
Maternal stress during pregnancy could obviously affect
development, with consequences for adult life. In addi-
tion, there might be an influence on the germ cells.
Thus, a true transgenerational effect should be detectable
in the third and possibly subsequent generations.
A recent study tested the effects of in utero exposure to
endocrine-disrupting chemicals on gene transcription and
DNAmethylation inmice and found that these are not in-
herited across generations (Iqbal et al. 2015). Likewise, the
offspring of human parents affected by thalidomide-in-
duced embryopathy did not display an increased occur-
rence of related defects (Smithells 1998; Strömland et al.
2002). A number of studies on mice found that paternal
environmental conditions, including diet, stress, and tox-
ins, have an impact on the offspring’s metabolic pheno-
types (Rando and Simmons 2015). Suggestively, several
of these studies observed changes in cytosinemethylation
that correlated with these phenotypes, raising the possi-
bility that differential methylation of the sperm DNA
might be a carrier of epigenetic inheritance. However, a
detailed study of dietary effects on the methylome of ma-
ture sperm failed to uncover a correlation between diet
and sperm DNA methylation (Shea et al. 2015). Rather,
stochastic individual differences in DNA methylation
(epivariation) turned out to be a much stronger contribu-
tor to the sperm methylome. These results argue against
sperm DNA methylation as the mediator of an inherited
effect of paternal diet on offspring metabolism. Epivaria-
tionwas found to be profoundly influenced by genetic var-
iation in DNA repeat elements, highlighting that inbred
mice are not isogenic and that this can have major con-
founding effects on interpreting epigenetic observations
(Shea et al. 2015). Moreover, population effects in sperm
can further obscure interpretations. The issues of geno-
typing and cell purity have also been highlighted as poten-
tial problems with current epigenome-wide association
(EWAS) studies (Birney et al. 2016). The difficulty in sepa-
rating genetic and environmental influences is illustrated
by the well-established epidemiological inverse correla-
tion between birthweight and risk for adultmetabolic dis-
eases (Hales and Barker 2001). This relationship has long
been attributed predominantly to the effects of poor ma-
ternal nutrition. Although the original studies empha-
sized developmental mechanisms, a connection with
epigenetic inheritance is frequently suggested. Recently,
van der Knaap and Verrijzer
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however, genetic effects were found to play a significant
role in the association between birth weight and adult dis-
ease (Horikoshi et al. 2016).
In summary, whereas epialleles have been described in
mammals, they are extremely rare (Daxinger and White-
law 2012; Heard and Martienssen 2014). A fundamental
aspect of development is the resetting of the genome, eras-
ing marks of gene activity or repression and allowing the
development of a new organism from a fertilized egg.
This cleaning of the epigenetic slate takes place during ga-
metogenesis and after fertilization and resets the genome
to start development (with a few exceptions, such as im-
printed genes). Given these considerations, we remain
skeptical that the impact of dietary or other nonmuta-
genic environmental stresses on chromatin structure
canmediate transgenerational effects inmammals. In par-
ticular, we see no evidence for the sometimes-made sug-
gestion that diet-induced heritable epigenetic states are
adaptive; e.g., by conferring a “thrifty” phenotype. Not
only is there nomolecular mechanism to explain such La-
marckian epigenetics, it is difficult to make evolutionary
sense of overruling germline reprogramming to burden
the next generation with parental epigenetic history.
Concluding remarks
There is accumulating evidence that central chromatin-
modifying enzymes respond to changes in the level of co-
factors and cosubstrates that are key metabolites. This
provides a molecular connection between cellular state
and environmental conditions, such as the availability
of nutrients or oxygen. A pertinent outstanding question
is whether metabolites have only global effects on chro-
matin or whether specific genes show a differential re-
sponse to changes in the levels of particular cofactors.
Although less studied, there are compelling examples of
metabolic enzymes that directly regulate local chromatin
structure and gene expression. Transcriptional control by
these double-dutymetabolic enzymes can be independent
of their canonical catalytic activity but still closely linked
to their metabolic role. These enzymes can act as tran-
scriptional coregulators recruited by sequence-specific
transcription factors, can themselves bind DNA, or may
generate niches of cofactor production to fuel local chro-
matin modifications. Metabolic signaling to chromatin
is an integral part of normal homeostasis, development,
aging, and disease. It has also become clear that the con-
trol of metabolism and gene expression forms a closely in-
tegrated network, including a multitude of feedback and
feed-forward loops rather than linear pathways. Although
there are a number of examples in which the involvement
of sequence-specific transcription factors explains gene
selectivity, generally, this aspect remains poorly under-
stood. Likewise, often it is not trivial to separate cause
and effect from mere correlations or bystander effects. Fi-
nally, its shear abundancemakes chromatin itself a poten-
tial modulator of cellular metabolism, which may affect
the cellular flux of acetate, acetyl-CoA, or SAM. Given
the well-established role of chromatin-modifying en-
zymes in diseases such as cancer, understanding how
their activities are influenced by metabolic state might
provide novel avenues for therapeutic intervention. We
anticipate that future research will further reveal the re-
ciprocal interconnectivity of metabolism, chromatin,
and gene expression.
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